Quick Takeaways
- PRICE T ROWE ASSOCIATES INC /MD/ filed SCHEDULE 13G/A for CELLDEX THERAPEUTICS INC COMMON STOCK (CLDX).
- Disclosed ownership: 3.6%.
- Date of event: 30 Sep 2025.
PRICE T ROWE ASSOCIATES INC /MD/ - 30 Sep 2025 SCHEDULE 13G/A Report for CELLDEX THERAPEUTICS INC COMMON STOCK (CLDX)
- Filing Manager
- PRICE T ROWE ASSOCIATES INC /MD/
- Reporting Manager
- T. Rowe Price Associates, Inc.
- Symbol
- CLDX
- Shares outstanding
- 66,186,139 shares
- Disclosed Ownership
- 2,382,701 shares
- Ownership
- 3.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 12:19:23 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"PRICE T ROWE ASSOCIATES INC /MD/ disclosed 3.6% ownership in CELLDEX THERAPEUTICS INC COMMON STOCK (CLDX) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 14 Nov 2025, 12:19.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 3.6% | 2,382,701 | 2,342,174 | 0 | Ellen York | Vice President |